Comparative analysis of the cardioprotective effects of candesartan combined with low-dose carvedilol or dexrazoxane in breast cancer patients on anthracycline chemotherapy
SHI Weili;WU Yingqi;Department of Cardiovascular Medicine,Chifeng Hospital;Department of Breast Surgery,Chifeng Hospital;
Objective To compare and investigate the cardioprotective effects of candesartan combined with lowdose carvedilol and dexrazoxane in breast cancer patients treated by anthracycline chemotherapy. Method The clinical data of 104 patients with breast cancer were retrospectively reviewed. The patients were divided into study group or control group(52 cases in each) by respective therapy administered. Patients in the control group were treated with dexrazoxane combined with chemotherapy regimen; while patients in study group were treated with candesartan combined with low-dose carvedilol. The changes of electrocardiogram, troponin, myocardial remodeling and adverse events were compared between the two groups before and after 4 and 8 cycles of treatment, respectively. Result After 8 cycles of treatment, the incidence of decreased QRS complex voltage, arrhythmia and ST-T abnormality in study group was significantly lower than that in the control group(P0.01). No significant difference was detected in LVEF, LVEDD and BNP between the two groups before chemotherapy(P0.05); greater decrease of LVEF, and more increase of LVEDD and BNP were observed in study group than in the control group after 4 and 8 cycles of chemotherapy(P0.01). No difference was detected in the incidence of troponin abnormalities after 4 cycles of chemotherapy in the two groups(P0.05), and there were no obvious abnormalities of troponin in the two groups during chemotherapy. No difference was noted in regard of the incidence of adverse reactions between the two groups(P0.05). Conclusion Candesartan combined with low-dose carvedilol can reduce the cardiac toxicities caused by anthracycline chemotherapy in cancer patients, with mild adverse reactions, and is clinically applicable in breast cancer patients during chemotherapy.
【CateGory Index】： R737.9